Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)

    Journal of the American Society of Nephrology Date published:

  • On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D

    Journal of the American Society of Nephrology Date published:

  • Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

    Journal of the American College of Cardiology Date published:

  • Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

    European Heart Journal Date published:

  • Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

    European Heart Journal Date published:

  • Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

    European Heart Journal Date published:

  • Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Cardiovascular Diabetology Date published:

  • Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Diabetes Care Date published:

  • Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy-Reply

    JAMA Date published:

  • Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

    The Lancet Diabetes & Endocrinology Date published:

  • Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

    Journal of the American Heart Association Date published:

  • Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease

    Clinical Pharmacology & Therapeutics Date published:

  • Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy

    European Heart Journal Date published:

  • Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

    Diabetes Care Date published:

  • The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

    Diabetes & Metabolism Date published: